Navigation Links
Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010
Date:2/10/2011

ccelerated depreciation related to restructuring.

(3) In 2010, to exclude charges related to the acquisition of Mepha GmbH, Mesoblast Limited and ChemGenex Pharmaceuticals Limited ($5.0M, $3.0M and $0.2M, respectively). In 2009, to exclude charges related to the acquisition of Arana Therapeutics Limited ($0.2M).  

(4) In 2010, to exclude the change in fair value of the Ception Therapeutics, Inc. (-$0.3M) and BioAssets Development Corporation ($0.5M) contingent consideration.

(5) To exclude costs related to restructurings.

(6) In 2009, to exclude the impairment of  our investment in SymBio Pharmaceuticals Limited.

(7) In 2010, to exclude the acquisition of worldwide license rights to Mesoblast Limited's proprietary technology platform.

(8) To exclude imputed interest expense associated with convertible debt.

(9) In 2010, to exclude the change in fair value of our investment in Mesoblast Limited ($12.0M), offset by the change in fair value of our investment in ChemGenex Pharmaceuticals Limited  ($4.1M).

(10) In 2010, to exclude a gain on foreign exchange of Australian Dollar acquisition funds ($2.0M) and proceeds received in a settlement ($6.5M).  

(11) To reflect the tax effect of pre-tax adjustments at applicable tax rates and certain other tax adjustments primarily related to changes in valuation allowances and other changes in tax assets and liabilities.

CEPHALON, INC. AND SUBSIDIARIESReconciliation of GAAP Net Income to Adjusted Net Income Attributable to Cephalon, Inc.(Unaudited)Year EndedDecember 31,20102009GAAP NET INCOME ATTRIBUTABLE TO CEPHALON, INC.

$ 425,745 $ 342,627 Cost of sales adjustments

154,713

(1)

113,021

(1)Research and development adjustments

4,715

(2)

4,747

(2)Selling, general and administrative adjustments

17,815

(3)

14,611

(3)Change in fair value of contingent
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
2. ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
3. Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder
4. Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
5. Cephalon to Webcast Investor Day
6. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
7. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
8. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
9. Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
10. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
11. Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
(Date:1/22/2015)... Calif. , Jan. 22, 2015  Amgen (NASDAQ: AMGN ... full year 2014 financial results on Tuesday, Jan. 27, 2015, after ... followed by a conference call with the investment community at 2 ... Robert A. Bradway , chairman and chief executive officer, and other ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... Late Stage Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc., today announced that it reported positive preclinical ... Association for the Study of Diabetes (EASD).  CCX140, ... the chemokine receptor CCR2, improved metabolic function while ... in an animal model, and was well tolerated ...
Cached Medicine Technology:immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 2ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 3ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 4
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has ... View website of AngelWeddingDress.com to find more ... dresses online for a bridal party. AngelWeddingDress offers a ... them. Its maternity wedding dresses are specially designed for ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the ... . , Auto insurance quotes help many drivers find ... necessary to call an agent or visit an agency for ... single website: http://autocarinsurancebest.com/ . , Every business who relies ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and ... relationship in an effort to further promote visibility and adoption ... has long made AMA journals available via its subscription services, ... JAMA Network. , Long known as both a ...
(Date:1/22/2015)... Richmond, VA (PRWEB) January 22, 2015 ... the power at the Science Museum of Virginia. Wicked ... 24. , Wicked Plants unearths 75 poisonous, carnivorous and ... traverse through each room to uncover the biochemical, physical ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... HealthDay Reporter , FRIDAY, Jan. 28 (HealthDay ... a decision by a drug manufacturer to halt production ... medication,s use in lethal injections in prison executions. ... Pentothal (sodium thiopental) at its plant in Italy, but ...
... cancer surgery may help activate the body,s immune response ... lowering mood disturbance, according to a new study by ... Center. The study is published in the ... It,s the first to examine the effects pre-surgery stress ...
... Dennis Thompson HealthDay Reporter , FRIDAY, Jan. 28 ... mantra for those who think people have become too reliant ... agree with the sentiment. They,re concerned that doctors are ... hands-on physical examination in favor of newfangled tests and scans. ...
... A team of researchers led by Vicente Gilsanz, ... Institute of Children,s Hospital Los Angeles, determined that the onset ... density, or bone strength. Length of puberty did not ... leads to osteoporosis, resulting in bones becoming increasingly brittle and ...
... Reporter , FRIDAY, Jan. 28 (HealthDay News) -- People facing ... by lack of control -- with doctors poking and prodding ... Hospice care, however, can give back some control over ... and helping both the dying person and the person,s family ...
... The Office of Naval Research,s (ONR) TechSolutions department is ... later this year new protective eyewear that will eliminate ... colored lenses to accommodate differences in light levels. ... transitional lenses commonly found at an optometrist,s office. "Transition ...
Cached Medicine News:Health News:Will Loss of Lethal Injection Drug Harm Surgical Patients? 2Health News:Will Loss of Lethal Injection Drug Harm Surgical Patients? 3Health News:Pre-surgical stress management boosts immune function, lowers mood disturbance in prostate cancer patients 2Health News:Pre-surgical stress management boosts immune function, lowers mood disturbance in prostate cancer patients 3Health News:Calls Go Out to Revive the Traditional Physical 2Health News:Calls Go Out to Revive the Traditional Physical 3Health News:Researchers discover age of onset of puberty predicts adult osteoporosis risk 2Health News:More People Choosing Hospice at Life's End 2Health News:More People Choosing Hospice at Life's End 3Health News:ONR's TechSolutions providing SEALs with new glasses that change lens color on the fly 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: